View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

AB InBev Becomes Official Beer Partner of FIFA Club World Cup 2025™​

NEW YORK--(BUSINESS WIRE)-- AB InBev (Euronext: ABI) (MEXBOL: ANB) (JSE: ANH) (NYSE: BUD), the world’s leading brewer, has extended its nearly 40-year partnership with FIFA to include the FIFA Club World Cup 2025™ taking place in the United States from June 15th to July 13th. AB InBev is also a sponsor of FIFA World Cup 2026™, which will be jointly hosted by 16 cities across Canada, Mexico and the United States. This press release features multimedia. View the full release here: AB InBev: Official Beer Partner of FIFA Club World Cup (Graphic: Business Wire) The expanded partnership reinforces...

Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures

Argenx : Efgartigimod enters phase III in myositis

>Positive phase II results - Argenx has announced positive results for the phase II of the phase II/III study (ALKIVIA) evaluating efgartigimod in patients with three sub-types of idiopathic inflammatory myopathies (or myositis). With no quantified press release for the time being, the group has indicated that the study demonstrates a statistically significant therapeutic effect in favour of efgartigimod on the total improvement score (TIS) at week 24 (primary endpoin...

Hilde Van Boxstael ... (+5)
  • Hilde Van Boxstael
  • Michiel Declercq
  • Sharad Kumar S.P
  • Thomas Vranken
  • Wim Lewi
Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures

Argenx : Efgartigimod passe en phase 3 dans les myosites

>Résultats de phase 2 positifs - Argenx annonce des résultats positifs de la partie phase 2 de la phase 2/3 (ALKIVIA) évaluant efgartigimod chez des patients dans trois sous-types de myopathies inflammatoires idiopathiques (ou myosites). Sans communiqué de résultats chiffrés à ce stade, la société indique que l’étude a démontré un effet thérapeutique en faveur d’efgartigimod statistiquement significatif sur le score total d’amélioration (TIS) à la semaine 24 (critère ...

Thomas Vranken
  • Thomas Vranken

argenx Myositis go & model update

argenx announced that it is advancing clinical development of SC efgar in idiopathic inflammatory myopathies (myositis). The ongoing seamless Ph2/3 study is a basket trial across three myositis subsets, IMNM, ASyS and DM, each of which will continue into the Ph3 part. Furthermore, following the strong Q3 update, we have adjusted our model to reflect the sustained strong commercial uptake for Vyvgart in myasthenia gravis (MG), as well as the solid start in CIDP. On the other hand, we have removed...

 PRESS RELEASE

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic ...

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in ALKIVIAPotential for efgartigimod SC to be first targeted approach for myositis patients who have limited treatment options November 20, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune dise...

Guy Sips ... (+6)
  • Guy Sips
  • Hilde Van Boxstael
  • Lynn Hautekeete
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi
Martin Marandon-Carlhian ... (+3)
  • Martin Marandon-Carlhian
  • Stephane Houri
  • Steven Boumans

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 11/13/2024

We maintain our Outperform rating on CaixaBank, one of our Top Picks in the sector, with a higher target of € 7.2 vs € 6.7 and ahead of the CMD on 19 November. We are lifting our net income estimates by 7% for 2025-2026, to 7% above the consensus. The strategic update is set to highlight the wisdom of the business model diversification (long-term savings) to address the current transition phase on rates. Despite a solid market performance, the profile does not look to be fully reflec...

Martin Marandon-Carlhian ... (+3)
  • Martin Marandon-Carlhian
  • Stephane Houri
  • Steven Boumans

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 13/11/2024

Nous réitérons notre opinion Surperformance sur CaixaBank, l’un de nos top picks du secteur, avec un OC porté à 7.2 € vs 6.7 € et en amont du CMD du 19/11. Nous relevons nos anticipations de RN de 7% sur 2025/2026 qui ressortent 7% supérieures au consensus. L’update stratégique devrait mettre en avant la pertinence de la diversification du business model (épargne LT) face à la transition actuelle sur les taux. Malgré un solide parcours boursier, cela n’est pas pleinement reflété dans ...

Florent Laroche-Joubert ... (+3)
  • Florent Laroche-Joubert
  • Roy Külter
  • Steven Boumans

ODDO : Spain: the PSOE and SUMAR looking to abolish the SOCIMI regime

>PSOE and Sumar spring a surprise in seeking to suddenly abolish the SOCIMI regime - On Monday 11 November, the PSOE reached a tax agreement with its Spanish government ally, “Sumar”, whereby the two parties want to abolish the SOCIMI REIT regime or at least part of its tax advantages. This sudden stance, which surprised Spanish property professionals, is thus different from the position that was presented just last week, namely to “encourage the construction of affor...

Florent Laroche-Joubert ... (+3)
  • Florent Laroche-Joubert
  • Roy Külter
  • Steven Boumans

ODDO : Espagne : le PSOE et SUMAR souhaiteraient abolir le régime SOCI...

>PSOE et Sumar créent la surprise en voulant supprimer soudainement le régime SOCIMI - Ce lundi 11 novembre, le PSOE sont parvenus à un accord fiscal avec son allié au gouvernement espagnol, « Sumar », par lequel les deux partis veulent supprimer le régime SOCIMI ou au moins une partie de ses avantages fiscaux. Cette prise de position soudaine qui a crée la surprise auprès des professionnels de l’immobilier espagnol, diffère ainsi de la position qui était encore mise ...

Lynn Hautekeete
  • Lynn Hautekeete

Risk of SOCIMI abolishment Fear of the SOCIMI abolishment stresses Eur...

Yesterday Spanish media reported on the potential abolishment of the SOCIMI status. The proposal comes from PSOE (socialists) and Sumar (Left winged). This is the REIT regime for listed companies that alows for a tax exemption. If this is the case corporate income tax would increase from 0% to 25%. It is very important to note that this measure is not yet approved. There is no visiblity yet on a potential alternative system. Additionally, measurements (cost shifts) could be taken to decrease the...

Reg Watson ... (+2)
  • Reg Watson
  • CFA

dsm-firmenich/Take your vitamins/BUY

dsm-firmenich expects to separate its Animal Nutrition and Health (ANH) business in 2025 which will complete the company's transformation into a flavours and fragrances business to rival Givaudan and Symrise. We model the impact of this on valuation and forecast the expected short-term boost from vitamin pricing. The outcome is that our adj. EBITDA forecasts for 2024-25F rise by c.10% each year but our valuation declines slightly to €146 per share, based on the disposal of ANH. We maintain our B...

Jacob Mekhael ... (+2)
  • Jacob Mekhael
  • Thibault Leneeuw
Jacob Mekhael
  • Jacob Mekhael

argenx Chinese NMPA approval for Vyvgart in CIDP

Yesterday before US market opens, argenx and partner Zai Lab announced China's national medical products administration (NMPA) approved the supplemental (sBLA) for Vyvgart Hytrulo in adults with CIDP. We anticipate approx. $600m in peak sales for CIDP in China, and pencil down 15% royalties to argenx from Zai Lab. Looking ahead, the candidate has been submitted to regulatory agencies in Europe and Japan, with approvals in CIDP expected in 2025, while regulatory submission in Canada is due by YE2...

 PRESS RELEASE

Corona Cero’s Relaxation Clause Brings a Fresh Perspective to Athlete ...

LONDON--(BUSINESS WIRE)-- Corona, the world’s most valuable beer brand, has introduced the ‘Relaxation Clause’, a new global initiative for all sponsorship agreements that ensures athletes dedicate time to relax and unwind as part of their contract with Corona Cero. This press release features multimedia. View the full release here: Brazilian surfer Gabriel Medina signs the Relaxation Clause (Photo: Business Wire) The Relaxation Clause offers a new approach to partnerships that reflects the essence of Corona: encouraging people to experience more moments to unwind and connect with nature. T...

 PRESS RELEASE

argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic In...

argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China First and only NMPA-approved treatment for patients with CIDP in China  Second VYVGART Hytrulo indication approved in China  November 11, 2024 – 7:30am ET  Amsterdam, the Netherlands— argenx SE (Euronext & Nasdaq: ARGX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) approved the supplemental Biologics License Application (sBLA) for VYVGART Hytrulo 1,000mg (5.6ml)/vial [efgartigimod alfa inject...

Argen X SE: 1 director

A director at Argen X SE sold 1,218 shares at 542.600EUR and the significance rating of the trade was 99/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch